Soluble implantable device comprising polyelectrolyte with hydrophobic counterions

Patent metadata

Field	Value
Publication number	US-9327062-B2
Application number	US-201514624063-A
Country	US
Kind code	B2
Filing date	Feb 17, 2015
Priority date	May 30, 2008
Publication date	May 3, 2016
Grant date	May 3, 2016

Abstract

The present invention provides an implantable device having a biosoluble coating comprising a polyelectrolyte and a counterion and the methods of making and using the same.

First claim

The invention claimed is:

1. An implantable device comprising a biosoluble body structure and optionally comprising a coating deposited on the body structure of the implantable device, the biosoluble body structure comprising:
a complex comprising a polyelectrolyte and a counterion, the polyelectrolyte being poly(2-acrylamido-2-methyl-1-propane sulfonic acid) (PAMPS), sulfonated poly(ether ether ketone) (SPEEK), poly(acryloxyethyltrimethyl ammonium chloride), poly(methacryloxy(2-hydroxy)propyltrimethyl ammonium chloride), or a combination thereof; wherein the implantable device is selected from the group consisting of stents, stent-grafts, catheters, grafts, pacemakers, defibrillators, leads for pacemakers, leads for defibrillators, electrodes for pacemakers, electrodes for defibrillators, artificial heart valves, anastomotic clips, arterial closure devices, patent foramen ovale closure devices, and cerebrospinal fluid shunts.

2. The implantable device of claim 1 , wherein the biosoluble body structure further comprises a bioactive agent.

3. The implantable device of claim 1 , wherein the counterion is a hydrophobic counterion.

4. The implantable device of claim 1 , wherein the complex has a high dissociation constant (pKa).

5. The implantable device of claim 2 , wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), biolimus, tacrolimus, dexamethasone, rapamycin, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578 ), γ-hiridun, clobetasol, pimecrolimus, imatinib mesylate, midostaurin, fenofibrate, and combinations thereof.

6. The implantable device of claim 1 , wherein the optional coating is present.

7. The implantable device of claim 1 , wherein the biosoluble body structure further comprises a biosoluble polymer selected from the group consisting of poly(ethylene glycol) (PEG), poly(lactide-co-glycolide)-co-poly(ethylene glycol) (PLGA-PEG) block copolymers, other PEG copolymers, poly(vinyl alcohol) (PVA), hyaluronic acid, hydroxyl cellulose, Carboxymethylcellulose (CMC), polysaccharides, phosphoryl choline containing polymers, chitosan, collagen, and combinations thereof.

8. The implantable device of claim 2 , wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), biolimus, tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578 ), γ-hiridun, clobetasol, pimecrolimus, imatinib mesylate, midostaurin, fenofibrate, and combinations thereof.

9. The implantable device of claim 1 , wherein the body structure of the implantable device is a.

10. The implantable device of claim 1 ,
wherein the polyelectrolyte is poly(2-acrylamido-2-methyl-1-propane sulfonic acid) (PAMPS), sulfonated poly(ether ether ketone) (SPEEK), or a combination thereof.

11. The implantable device of claim 1 , wherein the polyelectrolyte is poly(acryloxyethyltrimethyl ammonium chloride), poly(methacryloxy(2-hydroxy) -propyltrimethyl ammonium chloride), or a combination thereof.

12. A method of fabricating an implantable device, comprising
forming a biosoluble body structure comprising:
a complex comprising a polyelectrolyte and a counterion, the polyelectrolyte being poly(2-acrylamido-2-methyl-1-propane sulfonic acid) (PAMPS), sulfonated poly(ether ether ketone) (SPEEK), poly(acryloxyethyltrimethyl ammonium chloride), poly(methacryloxy(2-hydroxy)propyltrimethyl ammonium chloride, or a combination thereof; wherein the implantable device is selected from the group consisting of stents, stent-grafts, catheters, grafts, pacemakers, defibrillators, leads for pacemakers, leads for defibrillators, electrodes for pacemakers, electrodes for defibrillators, artificial heart valves, anastomotic clips, arterial closure devices, patent foramen ovale closure devices, and cerebrospinal fluid shunts.

13. The method of claim 12 , wherein the implantable device further comprises a bioactive agent.

14. The method of claim 12 , wherein the counterion is a hydrophobic counterion.

15. The method of claim 12 , wherein the complex has a high dissociation constant (pKa).

16. The method of claim 13 , wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), biolimus, tacrolimus, dexamethasone, rapamycin, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40 -O-[(2-hydroxy)ethoxy ]ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578 ), γ-hiridun, clobetasol, pimecrolimus, imatinib mesylate, midostaurin, fenofibrate, and combinations thereof.

17. The method of claim 12 , further comprising depositing a coating on the biosoluble body structure.

18. The method of claim 12 , wherein the biosoluble body structure is a stent.

19. The method of claim 12 , wherein the biosoluble body structure further comprises a biosoluble polymer selected from the group consisting of poly(ethylene glycol) (PEG), poly(lactide-co-glycolide)-co-poly(ethylene glycol) (PLGA-PEG) block copolymers, other PEG copolymers, poly(vinyl alcohol) (PVA), hyaluronic acid, hydroxyl cellulose, Carboxymethylcellulose (CMC), polysaccharides, phosphoryl choline containing polymers, chitosan, collagen, and combinations thereof.

20. The method of claim 13 , wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), biolimus, tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578 ), γ-hiridun, clobetasol, pimecrolimus, imatinib mesylate, midostaurin, fenofibrate, and combinations thereof.

Assignees

• Abbott Cardiovascular Systems

Inventors

• Hossainy Syed F A
• Trollsas O Mikael
• Kleiner Lothar W

Classifications

• A61L31/048

  obtained by reactions only involving carbon-to-carbon unsaturated bonds (A61L31/041 takes precedence) · CPC title

• C08L5/08

  Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof · CPC title

• C08L1/286

  substituted with acid radicals, e.g. carboxymethyl cellulose [CMC] (C08L1/282 takes precedence) · CPC title

• C09D189/00

  Coating compositions based on proteins; Coating compositions based on derivatives thereof (foodstuff preparations A23J3/00) · CPC title

• A61L31/10

  Macromolecular materials · CPC title